CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
CVRx (NASDAQ: CVRX) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The presentation begins at 3:45 p.m. PT and will be available via live webcast at the company's investor site. An archived recording will be posted after the live event and accessible at the same URL for a limited time.
This is a company investor presentation and not an earnings release or regulatory filing.
Positive
- None.
Negative
- None.
News Market Reaction – CVRX
In the Dec 22 session, CVRX declined 2.62%, reflecting a moderate negative market reaction. Argus tracked a trough of -6.7% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Conference participation | Neutral | -1.1% | Management fireside chat at Piper Sandler healthcare conference webcast to investors. |
| Nov 05 | Earnings results | Positive | -2.0% | Q3 2025 revenue growth, higher gross margin, narrowed net loss and updated guidance. |
| Nov 04 | Conference presentation | Neutral | -3.6% | Management presentation at Jefferies Global Healthcare Conference with live webcast. |
| Oct 22 | Earnings scheduling | Neutral | +1.5% | Announcement of Q3 2025 earnings release date and accompanying conference call details. |
| Aug 04 | Earnings results | Positive | -9.9% | Q2 2025 revenue growth, favorable CMS payment proposals, but ongoing net loss reported. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent CVRx news, including earnings and conference appearances, was often followed by modestly negative next-day moves, even when fundamentals like revenue growth and margins improved.
This announcement continues a pattern of CVRx highlighting investor-relations events after reporting strengthening fundamentals. In Q2 2025 and Q3 2025, the company posted revenue growth with improving gross margins and reiterated or refined guidance, yet shares moved lower after those earnings. The company has also regularly participated in healthcare conferences, such as Jefferies in November 2025 and Piper Sandler in December 2025, which provided visibility but did not trigger sustained positive price reactions ahead of this J.P. Morgan appearance.
Key Terms
neuromodulation medical
cardiovascular diseases medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MINNEAPOLIS, Dec. 22, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026. The Company's presentation will begin at 3:45 p.m. (PT).
A live webcast of the event can be found at ir.cvrx.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Healthcare
443-213-0501
ir@cvrx.com
Media Contact:
Emily Meyers
CVRx, Inc.
763-416-2853
emeyers@cvrx.com
